
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is expected to see significant growth in revenues and market share through collaborations, acquisitions, and expansions. The company has faced regulatory uncertainty and may require additional financing before reaching positive cash flow. With a strong presence in both liquid biopsy and tissue-based genomic profiling, along with plans to launch new tests, GH remains a strong contender in the precision oncology diagnostics market but may need to increase sales and marketing efforts to stay ahead of the competition.
Bears say
Guardant Health is a leading provider of liquid-based cancer tests, with a strong market position and a diverse portfolio of products and services. However, the company faces challenges in a growingly competitive market with other companies entering the space and potentially limiting Guardant's ability to command a price premium. Additionally, the company's long-term growth potential may be impacted by negative regulatory and payer dynamics in the reproductive health market. As a result, the outlook for Guardant's stock is negative as these factors could potentially lead to lower profitability and slower growth than expected.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares